Source comparison
PT-141 for Sexual Dysfunction: Clinical Comparison Table
Before diving into specific scenarios, understanding how PT-141 compares to conventional treatments clarifies where it fits within sexual dysfunction research protocols. PT-141 (Bremelanotide) MC3R/MC4R agonism in hypothalamus. Activates central desire pathway
This comparison does not assign a generated winner or score.
- Before diving into specific scenarios, understanding how PT-141 compares to conventional treatments clarifies where it fits within sexual dysfunction research protocols.
- PT-141 (Bremelanotide)
- MC3R/MC4R agonism in hypothalamus. Activates central desire pathways
- 45–90 minutes
- 6–12 hours
- Hypoactive sexual desire disorder (HSDD), low libido with intact vascular function
- Nausea (40%), flushing (20%), transient BP elevation
- Best for central desire deficits; requires advance planning due to onset delay; subcutaneous injection limits spontaneity
- Sildenafil (Viagra)
- PDE5 inhibition. Enhances cGMP-mediated vasodilation in penile tissue
- 30–60 minutes
- 4–6 hours
- Erectile dysfunction due to vascular insufficiency
- Headache, flushing, dyspepsia, visual disturbances
- First-line for ED with vascular etiology; ineffective for low libido; requires sexual stimulation to work
- Tadalafil (Cialis)
- PDE5 inhibition with longer half-life. Same vasodilatory mechanism as sildenafil
- 30–120 minutes
- 24–36 hours
- Erectile dysfunction, daily low-dose for continuous effect
- Headache, back pain, myalgia, flushing
- Longer therapeutic window allows spontaneity; still requires intact desire; no effect on libido itself
- Flibanserin (Addyi)
- 5-HT1A agonist and 5-HT2A antagonist. Modulates serotonin and dopamine balance
- Daily dosing (4–8 weeks to effect)
- Continuous with daily use
- Female HSDD (premenopausal)
- Dizziness, somnolence, nausea, hypotension with alcohol
- Requires daily adherence; alcohol contraindication; effect size modest (0.5–1 additional SSE/month)
- Testosterone Replacement
- Androgen receptor activation. Increases baseline libido, energy, and sexual motivation
- 2–6 weeks (variable by formulation)
- Continuous with ongoing therapy
- Hypogonadism (low testosterone) in men and women
- Acne, polycythemia, prostate concerns (men), virilization (women)
- Effective when deficiency confirmed by lab; contraindicated in hormone-sensitive cancers; not a short-term solution